تداخلات راساجيلين

CONTRAINDICATIONS IOPIDINE 1% Ophthalmic Solution is contraindicated for patients receiving monoamine oxidase inhibitor therapy and for patients with hypersensitivity to any component of this medication or to clonidine. (نشرة أبراكلونيدين، موانع الاستعمال)

Taking, or within 14 days of stopping, a monoamine oxidase inhibitor (MAOI) [see Drug Interactions (7) ] . (نشرة أتوموكسيتين، موانع الاستعمال)

John’s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor ( 4 ) (نشرة راساجيلين، موانع الاستعمال)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

…Precautions (5.2) ] • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [ see Warnings and Precautions (5.5) ] • Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [ see Warnings and Precautions (5.7), Drug Interactions (7) ] • Known or suspected gastrointestinal obstruction,… (نشرة البلادونا والأفيون، موانع الاستعمال)

Selective Serotonin Reuptake Inhibitors/Serotonin and Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs and MAO inhibitors [see Warnings and Precautions (5.7) ]. (نشرة إليتريبتان، التداخلات الدوائية)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (نشرة أمفيتامين، موانع الاستعمال)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (نشرة أمفيتامين وديكستروأمفيتامين، موانع الاستعمال)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.3) ] . (نشرة أوكسيكودون، التداخلات الدوائية)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions ( 5.2)]. (نشرة أوكسيكودون وباراسيتامول، التداخلات الدوائية)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (نشرة أوكسيمورفون، التداخلات الدوائية)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة أوليسيريدين، التداخلات الدوائية)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (نشرة أوندانسيترون، التحذيرات والاحتياطات)

John’s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor ( 4 ) (نشرة راساجيلين، موانع الاستعمال)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

…respiratory depression ( see WARNINGS ). acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment ( see WARNINGS ). concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days ( see WARNINGS ). known or suspected gastrointestinal obstruction, including paralytic ileus ( see WARNINGS… (نشرة باراسيتامول وكودايين، موانع الاستعمال)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

Rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. (نشرة راساجيلين، موانع الاستعمال)

Rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. (نشرة راساجيلين، موانع الاستعمال)

Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within 14 days [ see Warnings and Precautions (5.16) , Drug Interactions (7.6) ]. (نشرة بروميثازين وكودايين، موانع الاستعمال)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بنتازوسين ونالوكسون، الاحتياطات)

Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. (نشرة بنزفيتامين، موانع الاستعمال)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (نشرة بوبرينورفين، التداخلات الدوائية)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma). (نشرة بوبرينورفين ونالوكسون، التداخلات الدوائية)

…respiratory depression [see Warnings and Precautions ( 5.9 ) ] Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment[see Warnings and Precautions ( 5.9 ) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ) / Drug Interactions ( 7 ) ]. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، موانع الاستعمال)

…Precautions ( 5.2 )] • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions ( 5.10 )] • Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.11 ), Drug Interactions ( 7 )] • Known or suspected gastrointestinal obstruction,… (نشرة بوتالبيتال وباراسيتامول وكافيين وكودايين، موانع الاستعمال)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بوتورفانول، الاحتياطات)

The use of monoamine oxidase inhibitors (MAOIs) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. (نشرة بوسبيرون، موانع الاستعمال)

Rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome [see Warnings and Precautions ( 5.2 )] . (نشرة راساجيلين، موانع الاستعمال)

…suspected paralytic ileus [see Warnings and Precautions (5.12) ] Hypersensitivity to tapentadol (e.g., anaphylaxis, angioedema) or to any other ingredients of the product [see Adverse Reactions (6.2) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Drug Interactions (7) ] Significant respiratory depression ( 4 ) (نشرة تابنتادول، موانع الاستعمال)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

Rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome [see Warnings and Precautions ( 5.2 )] . (نشرة راساجيلين، موانع الاستعمال)

Rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome [see Warnings and Precautions ( 5.2 )] . (نشرة راساجيلين، موانع الاستعمال)

…concomitant use of an antidepressant (e.g., selective serotonin reuptake inhibitors-SSRIs, serotonin-norepinephrine reuptake inhibitors-SNRIs, tricyclic antidepressants, tetracyclic antidepressants, triazolopyridine antidepressants) and a nonselective MAOI (e.g., phenelzine, tranylcypromine) or selective MAO-B inhibitors, such as selegiline (Eldepryl) and rasagiline . (نشرة راساجيلين، التحذيرات والاحتياطات)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

• Taking monoamine oxidase inhibitors (MAOIs). (نشرة تيترابينازين، موانع الاستعمال)

However, based on mechanism of action, the use of non-selective MAO inhibitors and linezolid should be avoided as there is a potential for increased blood pressure when taken with NORTHERA. (نشرة دروكسيدوبا، التداخلات الدوائية)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

…Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets [ see Drug Interactions… (نشرة دوكسيلامين وبيريدوكسين، موانع الاستعمال)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result. (نشرة ديثيل بروبيون، موانع الاستعمال)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

Avoid use of diphenoxylate hydrochloride and atropine sulfate in patients who take MAOIs and monitor for signs and symptoms of hypertensive crisis (headache, hyperthermia, hypertension). (نشرة ديفينوكسيلات وأتروبين، التداخلات الدوائية)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Drug Interactions ]. (نشرة ديكستروأمفيتامين، موانع الاستعمال)

Rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. (نشرة راساجيلين، موانع الاستعمال)

Rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. (نشرة راساجيلين، موانع الاستعمال)

Antihistamines are also contraindicated in the following conditions: Hypersensitivity to dexchlorpheniramine maleate or other antihistamines of similar chemical structure Monoamine oxidase inhibitor therapy (See Drug Interaction section) (نشرة ديكسكلورفينيرامين، موانع الاستعمال)

• Concomitant treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises [see Drug Interactions ( 7.1 )] . (نشرة ديكسميثيل فينيدات، موانع الاستعمال)

Taking monoamine oxidase inhibitors (MAOIs). (نشرة ديوتيترابينازين، موانع الاستعمال)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (نشرة ريزاتريبتان، التداخلات الدوائية)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة ريميفنتانيل، التحذيرات والاحتياطات)

• Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs. (نشرة زيبراسيدون، موانع الاستعمال)

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (نشرة سودوإيفيدرين، التحذيرات)

Concomitant use of rasagiline with one of many classes of antidepressants (e.g., SSRIs, SNRIs, triazolopyridine, tricyclic or tetracyclic antidepressants) is not recommended [see Drug Interactions ( 7.5 )]. (نشرة راساجيلين، التحذيرات والاحتياطات)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)] . (نشرة سوماتريبتان، التداخلات الدوائية)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (نشرة سوماتريبتان ونابروكسين، التداخلات الدوائية)

Monoamine oxidase inhibitor therapy (See DRUG INTERACTIONS ). (نشرة سيبروهيبتادين، موانع الاستعمال)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

John’s wort and with cyclobenzaprine. (نشرة راساجيلين، موانع الاستعمال)

…concomitant use of an antidepressant (e.g., selective serotonin reuptake inhibitors-SSRIs, serotonin-norepinephrine reuptake inhibitors-SNRIs, tricyclic antidepressants, tetracyclic antidepressants, triazolopyridine antidepressants) and a nonselective MAOI (e.g., phenelzine, tranylcypromine) or selective MAO-B inhibitors, such as selegiline (Eldepryl) and rasagiline . (نشرة راساجيلين، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of granisetron and other serotonergic drugs. (نشرة غرانيسيترون، التحذيرات والاحتياطات)

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (نشرة فالبينازين، التداخلات الدوائية)

Selective Serotonin Reuptake Inhibitors / Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during combined use of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [ see Warnings and Precautions (5.7) ]. (نشرة فروفاتريبتان، التداخلات الدوائية)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة فنتانيل، التحذيرات والاحتياطات)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

Qelbree is contraindicated in patients: receiving concomitant treatment with monoamine oxidase inhibitors (MAOI), or within 14 days following discontinuing an MAOI, because of an increased risk of hypertensive crisis [see Drug Interactions (7.1) ] . receiving concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic… (نشرة فيلوكسازين، موانع الاستعمال)

…cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (نشرة فينترمين، موانع الاستعمال)

…Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] With glaucoma [see Warnings and Precautions (5.3) ] With hyperthyroidism Taking or within 14 days of stopping a monoamine oxidase inhibitors [see Drug Interactions (7) ] With known hypersensitivity to phentermine, topiramate or any of the excipients in phentermine and topiramate extended-release… (نشرة فينترمين وتوبيرامات، موانع الاستعمال)

…coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension, pulmonary hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy (see PRECAUTIONS, Pregnancy ) • Nursing • Use in combination with other… (نشرة فينديميترازين، موانع الاستعمال)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

John’s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor ( 4 ) (نشرة راساجيلين، موانع الاستعمال)

Concomitant use of monoamine oxidase inhibitors (MAOIs). (نشرة كاربامازيبين، موانع الاستعمال)

Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with levodopa or carbidopa-levodopa combination products with or without carbidopa. (نشرة كاربيدوبا، موانع الاستعمال)

DUOPA is contraindicated in patients who are currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 2 weeks) taken a nonselective MAO inhibitor. (نشرة كاربيدوبا وليفودوبا، موانع الاستعمال)

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (نشرة كاربيدوبا وليفودوبا وإنتاكابون، موانع الاستعمال)

…because deaths have been reported in this age group [see Warnings and Precautions (5.1)]. patients who are hypersensitive to carbinoxamine maleate or any of the inactive ingredients in Carbinoxamine Maleate Extended-Release Oral Suspension [see Warnings and Precautions (5.4)]. patients who are taking monoamine oxidase inhibitors (MAOI) [see Drug Interactions (7)]. (نشرة كاربينوكسامين، موانع الاستعمال)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

• Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ), Drug Interactions ( 7 )]. (نشرة كودايين، موانع الاستعمال)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions (5.7) and Drug Interactions (7.1) ] . (نشرة ليسديكسامفيتامين، موانع الاستعمال)

INBRIJA is contraindicated in patients currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or who have recently (within 2 weeks) taken a nonselective MAO inhibitor. (نشرة ليفودوبا، موانع الاستعمال)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة ليفورفانول، الاحتياطات)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

John’s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor ( 4 ) (نشرة راساجيلين، موانع الاستعمال)

• Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.9 ) and Drug Interactions ( 7 )]. (نشرة مورفين، موانع الاستعمال)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (نشرة ميتاكسالون، التداخلات الدوائية)

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, avoid use in patients with hypertension or in patients taking monoamine oxidase inhibitors [see Drug Interactions ( 7.1 )] . (نشرة ميتوكلوبراميد، التحذيرات والاحتياطات)

Rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome [see Warnings and Precautions ( 5.2 )] . (نشرة راساجيلين، موانع الاستعمال)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (نشرة ميثامفيتامين، موانع الاستعمال)

CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (نشرة ميثيل دوبا، موانع الاستعمال)

Concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor because of the risk of hypertensive crisis [see Drug Interactions (7.1) ]. (نشرة ميثيل فينيدات، موانع الاستعمال)

Avoid use of MAO inhibitors or linezolid with midodrine. (نشرة ميدودرين، التداخلات الدوائية)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

Concomitant use of rasagiline with one of many classes of antidepressants (e.g., SSRIs, SNRIs, triazolopyridine, tricyclic or tetracyclic antidepressants) is not recommended [see Drug Interactions ( 7.5 )]. (نشرة راساجيلين، التحذيرات والاحتياطات)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)] . (نشرة ناراتريبتان، التداخلات الدوائية)

Monoamine Oxidase Inhibitors (MAOIs) MAOI (e.g., phenelzine, tranylcypromine, linezolid) interactions with opioids may manifest as serotonin syndrome [see PRECAUTIONS; Drug Interactions ] or opioid toxicity (e.g., respiratory depression, coma [see WARNINGS ]). (نشرة نالبوفين، التداخلات الدوائية)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

الجمع بين نبتة سانت جون ومضادات الاكتئاب والأدوية السيروتونينية الأخرى يزيد خطر متلازمة السيروتونين. (NCCIH, St. John's Wort)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

May cause serotonin syndrome when used with antidepressants ( 5.2 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.3) ] . (نشرة هيدروكودون، التداخلات الدوائية)

Monoamine Oxidase Inhibitors (MAOIs) MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma). (نشرة هيدروكودون وإيبوبروفين، التداخلات الدوائية)

The use of hydrocodone bitartrate and acetaminophen tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. (نشرة هيدروكودون وباراسيتامول، التداخلات الدوائية)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وكلورفينيرامين، التداخلات الدوائية)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وهوماتروبين، التداخلات الدوائية)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions ( 5.3 )]. (نشرة هيدرومورفون، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression. (نشرة إستازولام، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Decreasing the levodopa dose may lessen or eliminate this side effect ( 5.7 ) (نشرة راساجيلين، التحذيرات والاحتياطات)

Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. (نشرة إنسولين أسبارت، التداخلات الدوائية)

…with LEVEMIR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (نشرة إنسولين ديتيمير، التداخلات الدوائية)

…Degludec Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (نشرة إنسولين ديغلوديك، التداخلات الدوائية)

…Significant Drug Interactions with AFREZZA Antidiabetic agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor blood glucose… (نشرة إنسولين عادي (بشري)، التداخلات الدوائية)

…Glargine-yfgn Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (نشرة إنسولين غلارجين، التداخلات الدوائية)

Clinically Significant Drug Interactions with LYUMJEV Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (نشرة إنسولين ليسبرو، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Concomitant Use with MAO Inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (نشرة إيزوفلوران، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

For this reason, prescribers should monitor patients for drowsiness or sleepiness, because some of the events occur well after initiation of treatment with dopaminergic medication. (نشرة راساجيلين، التحذيرات والاحتياطات)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

For this reason, prescribers should monitor patients for drowsiness or sleepiness, because some of the events occur well after initiation of treatment with dopaminergic medication. (نشرة راساجيلين، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors (MAOI) Drug interactions, including an increased incidence of extrapyramidal effects, have been reported when some MAOI and phenothiazines are used concomitantly. (نشرة بروميثازين، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Monoamine oxidase inhibitors may result in increased hypotension. (نشرة بريمونيدين، التداخلات الدوائية)

Monoamine oxidase inhibitors may result in increased hypotension. (نشرة بريمونيدين وتيمولول، التداخلات الدوائية)

…of Adverse Reactions Due to Drug Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors… (نشرة بوبيفاكايين، التحذيرات والاحتياطات)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. (نشرة بوتالبيتال وباراسيتامول، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (نشرة بيوغليتازون وغليميبيريد، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

…1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance,… (نشرة دروبيريدول، التحذيرات)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

…be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (نشرة ديازيبام، التداخلات الدوائية)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (نشرة ديسيكلومين، التداخلات الدوائية)

Ciprofloxacin or Other CYP1A2 Inhibitors Rasagiline plasma concentrations may increase up to 2 fold in patients using concomitant ciprofloxacin and other CYP1A2 inhibitors. (نشرة راساجيلين، التحذيرات والاحتياطات)

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines. (نشرة ديفينهيدرامين، التداخلات الدوائية)

For this reason, prescribers should monitor patients for drowsiness or sleepiness, because some of the events occur well after initiation of treatment with dopaminergic medication. (نشرة راساجيلين، التحذيرات والاحتياطات)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Ciprofloxacin or Other CYP1A2 Inhibitors Rasagiline plasma concentrations may increase up to 2 fold in patients using concomitant ciprofloxacin and other CYP1A2 inhibitors. (نشرة راساجيلين، التحذيرات والاحتياطات)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (نشرة سكسينيل كولين، التداخلات الدوائية)

…with rasagiline, patients should be advised of the potential to develop drowsiness and specifically asked about factors that may increase the risk with rasagiline such as concomitant sedating medications, the presence of sleep disorders, and concomitant medications that increase rasagiline plasma levels (e.g., ciprofloxacin) [see Drug Interactions ( 7.6 )] . (نشرة راساجيلين، التحذيرات والاحتياطات)

Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (نشرة سيفوفلوران، التداخلات الدوائية)

Ciprofloxacin or Other CYP1A2 Inhibitors Rasagiline plasma concentrations may increase up to 2 fold in patients using concomitant ciprofloxacin and other CYP1A2 inhibitors. (نشرة راساجيلين، التحذيرات والاحتياطات)

…Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. (نشرة غليبنكلاميد، التداخلات الدوائية)

…increase the susceptibility to and/or intensity of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory… (نشرة غليبيزيد، التداخلات الدوائية)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (نشرة غليبيزيد وميتفورمين، الاحتياطات)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (نشرة غليميبيريد، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

For this reason, prescribers should monitor patients for drowsiness or sleepiness, because some of the events occur well after initiation of treatment with dopaminergic medication. (نشرة راساجيلين، التحذيرات والاحتياطات)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (نشرة كارفيديلول، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Ciprofloxacin or Other CYP1A2 Inhibitors Rasagiline plasma concentrations may increase up to 2 fold in patients using concomitant ciprofloxacin and other CYP1A2 inhibitors. (نشرة راساجيلين، التحذيرات والاحتياطات)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (نشرة كلورازيبات، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (نشرة كلوروبروكايين، الاحتياطات)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (نشرة كلونازيبام، التداخلات الدوائية)

Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines. (نشرة كليماستين، التداخلات الدوائية)

Monoamine-oxidase inhibitors: Concomitant administration may potentiate the effects and toxicity of monoamine-oxidase inhibitors. (نشرة كوكايين، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (نشرة ليدوكايين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (نشرة ميبيفاكايين، التحذيرات)

Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. (نشرة ميتوبرولول، التداخلات الدوائية)

Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. (نشرة ميتوبرولول وهيدروكلوروثيازيد، التداخلات الدوائية)

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (نشرة راساجيلين، التداخلات الدوائية)

Ciprofloxacin or Other CYP1A2 Inhibitors Rasagiline plasma concentrations may increase up to 2 fold in patients using concomitant ciprofloxacin and other CYP1A2 inhibitors. (نشرة راساجيلين، التحذيرات والاحتياطات)

…Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid,… (نشرة ناتيغلينيد، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Drug Interactions MAO inhibitors should be used with caution in patients receiving hydralazine. (نشرة هيدرالازين، التداخلات الدوائية)

It is theoretically possible, therefore, that the combination of Entacapone Tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. (نشرة إنتاكابون، التحذيرات)

Antidepressants: The hypotensive effect of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers. (نشرة بروبرانولول، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

It is theoretically possible, therefore, that the combination of Tolcapone tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. (نشرة تولكابون، التحذيرات)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (نشرة تيربينافين، التداخلات الدوائية)

Drug Interactions Since the chemical structure of difenoxin hydrochloride is similar to meperidine hydrochloride, the concurrent use of MOTOFEN ® with monoamine oxidase inhibitors may, in theory, precipitate a hypertensive crisis. (نشرة ديفينوكسين وأتروبين، التداخلات الدوائية)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (نشرة ريباغلينيد، التداخلات الدوائية)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (نشرة زولميتريبتان، التحذيرات والاحتياطات)

Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (نشرة غليبنكلاميد وميتفورمين، التداخلات الدوائية)